GRANULESNSEGranules India Limited· PharmaceuticalsMinimalNeutral
Announced Wed, 29 Apr · 14:49 IST

Monitoring Agency Report for the Quarter ended on March 31, 2026.

Related Party TransactionsCompliance View source PDF

GRANULES · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-0.3%1-day move
₹703.00
prior close
₹708.05
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.1+0.0-0.5-0.2-0.3-0.3+1.6+4.7+5.7+7.4+8.8+10.7+13.2
Up moveDown movePending
AI summary

Granules India Limited has filed its quarterly Monitoring Agency Report for the Q4 FY26 ended March 31, 2026, submitted by India Ratings & Research Private Limited. The company raised INR 1,762.50 Crores through a preferential issue (February 10-23, 2026), comprising equity shares (INR 300 Cr) and convertible warrants (INR 1,462.50 Cr). As of March 31, 2026, INR 665.63 Crores was received (full equity + 25% upfront for warrants). Of the amount raised, INR 218.14 Crores has been utilized, leaving INR 447.48 Crores unutilized. Key utilization included General Corporate Purposes (INR 44.21 Cr for salaries), vendor payments (INR 135.64 Cr), working capital (INR 17.12 Cr), capex (INR 5.01 Cr), and operating expenses (INR 16.17 Cr). The company also made an INR 400 Cr equity investment in its wholly-owned subsidiary Granules Life Sciences Private Limited. No deviations from the stated objects of the issue were observed.

Likely market impact

The filing indicates normal utilization of preferential issue proceeds without any deviation from disclosed objects. The significant unutilized balance (INR 447.48 Cr) is parked in FDs and subsidiary balance, suggesting planned deployment in future quarters. This is a routine compliance filing with no immediate impact on the stock, though gradual utilization will be tracked by investors.